Scarica l'app Stockscreener
138.02
6.35%
-9.36
Dopo l'orario di chiusura:
138.00
-0.02
-0.01%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$147.38
Aprire:
$140
Volume 24 ore:
3.01M
Relative Volume:
3.29
Capitalizzazione di mercato:
$13.69B
Reddito:
$2.41B
Utile/perdita netta:
$305.80M
Rapporto P/E:
46.79
EPS:
2.95
Flusso di cassa netto:
$492.20M
1 W Prestazione:
-2.44%
1M Prestazione:
-1.60%
6M Prestazione:
+28.70%
1 anno Prestazione:
+18.79%
Intervallo 1D:
$133.61
$144.30
Intervallo di 1 settimana:
$133.61
$149.98
Portata 52W:
$84.23
$154.61
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Nome
Neurocrine Biosciences Inc
Settore
Telefono
(858) 617-7600
Indirizzo
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Confronta NBIX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
138.02 | 14.62B | 2.41B | 305.80M | 492.20M | 2.95 |
|
ZTS
Zoetis Inc
|
143.94 | 64.44B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.77 | 44.53B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.05 | 40.61B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.23 | 22.69B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
455.32 | 18.78B | 3.08B | 1.24B | 1.07B | 25.61 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-21 | Iniziato | Citigroup | Buy |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-07-10 | Iniziato | Goldman | Buy |
| 2025-04-15 | Aggiornamento | Needham | Hold → Buy |
| 2025-04-14 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | Iniziato | Deutsche Bank | Hold |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-08-29 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | Ripresa | Citigroup | Neutral |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-10-24 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-08-21 | Reiterato | Mizuho | Neutral |
| 2023-07-24 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | Aggiornamento | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-03-30 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-02-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-10-11 | Iniziato | UBS | Buy |
| 2022-09-26 | Iniziato | Wells Fargo | Equal Weight |
| 2022-06-06 | Ripresa | Jefferies | Buy |
| 2022-03-03 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-01-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | Iniziato | BMO Capital Markets | Underperform |
| 2021-11-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-10-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Ripresa | Needham | Hold |
| 2021-08-06 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | Ripresa | Goldman | Neutral |
| 2021-05-06 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2021-02-02 | Iniziato | Raymond James | Outperform |
| 2020-09-30 | Iniziato | The Benchmark Company | Hold |
| 2020-08-04 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-06-29 | Downgrade | Goldman | Buy → Neutral |
| 2020-06-09 | Iniziato | Wedbush | Outperform |
| 2020-03-06 | Iniziato | Citigroup | Buy |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-24 | Iniziato | William Blair | Outperform |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2020-02-05 | Reiterato | H.C. Wainwright | Buy |
| 2019-12-13 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-07-16 | Iniziato | Oppenheimer | Outperform |
| 2019-06-05 | Iniziato | Guggenheim | Neutral |
| 2019-05-21 | Iniziato | Credit Suisse | Outperform |
| 2019-04-22 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-02-06 | Reiterato | BofA/Merrill | Buy |
| 2019-01-23 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-12-13 | Iniziato | Goldman | Buy |
| 2018-11-21 | Iniziato | Canaccord Genuity | Buy |
Mostra tutto
Neurocrine Biosciences Inc Borsa (NBIX) Ultime notizie
Deutsche Bank Adjusts Neurocrine Biosciences Price Target to $142 From $140, Maintains Hold Rating - MarketScreener
Morgan Stanley Raises Price Target on Neurocrine Biosciences to $178 From $168, Keeps Overweight Rating - MarketScreener
Why Neurocrine Biosciences Inc. (NB3) stock could rally stronglyJuly 2025 Setups & Verified Momentum Stock Watchlist - newser.com
Will Neurocrine Biosciences Inc. (NB3) stock boost dividends furtherStop Loss & AI Driven Price Forecasts - newser.com
What data driven models say about Neurocrine Biosciences Inc.’s futureJuly 2025 PreEarnings & Risk Controlled Daily Trade Plans - newser.com
Is it time to cut losses on Neurocrine Biosciences Inc.July 2025 Highlights & Consistent Growth Stock Picks - newser.com
Neurocrine Biosciences Q3 2025 Earnings Call Transcript - MarketBeat
What earnings revisions data tells us about Neurocrine Biosciences Inc.Quarterly Profit Report & Daily Market Momentum Tracking - newser.com
Neurocrine: Q3 Earnings Snapshot - Stamford Advocate
Neurocrine Biosciences Beats Estimates But Wall Street Punishes The Stock - Yahoo Finance
Here's What Key Metrics Tell Us About Neurocrine (NBIX) Q3 Earnings - sharewise.com
Neurocrine Biosciences Tops Q3 Estimates With Growing Sales - Finimize
Neurocrine Biosciences (NBIX) Q3 Earnings and Revenues Top Estimates - Yahoo Finance
Neurocrine Biosciences reports 28% jump in Q3 net sales, EPS beats estimates - MarketScreener
Earnings Flash (NBIX) Neurocrine Biosciences, Inc. Reports Q3 Revenue $794.9M, vs. FactSet Est of $746.8M - MarketScreener
Earnings Flash (NBIX) Neurocrine Biosciences, Inc. Posts Q3 Adjusted EPS $2.17 per Share, vs. FactSet Est of $2.07 - MarketScreener
Neurocrine Biosciences shares rise as Q3 earnings, revenue beat expectations - Investing.com
Neurocrine Biosciences Reports Third Quarter 2025 Financial Results - PR Newswire
What RSI levels show for Neurocrine Biosciences Inc. (NB3) stockJuly 2025 Final Week & Free Weekly Chart Analysis and Trade Guides - newser.com
Can Neurocrine Biosciences Inc. stock sustain revenue growthQuarterly Market Summary & AI Enhanced Execution Alerts - newser.com
Is Neurocrine Biosciences Inc. (NB3) stock a buy during volatile marketsMarket Trend Review & Free Real-Time Volume Trigger Notifications - newser.com
Is Neurocrine Biosciences Inc. (NB3) stock vulnerable to rate hikesEarnings Overview Summary & Expert Approved Momentum Ideas - newser.com
Can Neurocrine Biosciences Inc. stock hit analyst price targetsWeekly Gains Report & Daily Risk Controlled Trade Plans - Fundação Cultural do Pará
Trend Recap: How rising interest rates impact Neurocrine Biosciences Inc. stockWeekly Risk Summary & Fast Entry and Exit Trade Plans - Fundação Cultural do Pará
How risky is Neurocrine Biosciences Inc. stock nowJuly 2025 Intraday Action & Fast Gain Stock Tips - newser.com
Short interest data insights for Neurocrine Biosciences Inc.Portfolio Risk Report & AI Driven Stock Movement Reports - newser.com
Will Neurocrine Biosciences Inc. (NB3) stock return to pre crash levelsMarket Rally & Risk Controlled Stock Pick Alerts - Fundação Cultural do Pará
How rising interest rates impact Neurocrine Biosciences Inc. stock2025 Institutional Moves & Consistent Growth Equity Picks - Fundação Cultural do Pará
What moving averages say about Neurocrine Biosciences Inc.Insider Selling & Low Risk High Win Rate Stock Picks - newser.com
Neurocrine Biosciences (NBIX): Fresh INGREZZA Study Data Renews Focus on Valuation - simplywall.st
Neurocrine Biosciences Experiences Revision in Its Stock Evaluation Amid Strong Market Performance - Markets Mojo
Neurocrine Biosciences Inc Azioni (NBIX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.19%
2.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):